We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Matsons
MATX
$7.13B
| $21.9K | ﹤0.01% |
282
-266
| -49% | -$18.2K |
|
1752
Lexicon Pharmaceuticals
LXRX
$894M
| $21.9K | ﹤0.01% |
+9,568
| New | +$25.4K |
|
1753
La-Z-Boy
LZB
$1.21B
| $21.6K | ﹤0.01% |
754
-585
| -44% | -$16.3K |
|
1754
Donnelley Financial Solutions
DFIN
$1.18B
| $21.5K | ﹤0.01% |
472
-412
| -47% | -$18.2K |
|
1755
Westamerica Bancorp
WABC
$1.39B
| $21.2K | ﹤0.01% |
553
-7,586
| -93% | -$303K |
|
1756
PDF Solutions
PDFS
$1.75B
| $21.2K | ﹤0.01% |
+469
| New | +$19.1K |
|
|
DNB
1757
DELISTED
Dun & Bradstreet
DNB
| $21.1K | ﹤0.01% |
1,827
| – | – |
|
1758
Invesco
IVZ
$13.6B
| $20.8K | ﹤0.01% |
1,239
-72
| -5% | -$1.16K |
|
|
BORR
1759
Borr Drilling
BORR
$1.35B
| $20.8K | ﹤0.01% |
2,764
-340,508
| -99% | -$2.44M |
|
1760
Franklin Templeton
BEN
$16.9B
| $20.8K | ﹤0.01% |
777
-80
| -9% | -$2.07K |
|
1761
iShares MSCI South Korea ETF
EWY
$27B
| $20.6K | ﹤0.01% |
325
| – | – |
|
1762
Perdoceo Education
PRDO
$2.06B
| $20.3K | ﹤0.01% |
1,655
+1,271
| +331% | +$16K |
|
1763
Titan Machinery
TITN
$571M
| $20.1K | ﹤0.01% |
682
-207,552
| -100% | -$6.26M |
|
|
HLVX
1764
DELISTED
HilleVax
HLVX
| $20.1K | ﹤0.01% |
1,170
-1,025
| -47% | -$15.9K |
|
1765
DocGo
DCGO
$38.1M
| $20K | ﹤0.01% |
2,139
-1,872
| -47% | -$16.4K |
|
|
TDAY
1766
USA Today Co
TDAY
$966M
| $19.8K | ﹤0.01% |
8,813
-687
| -7% | -$1.37K |
|
1767
Marqeta
MQ
$1.67B
| $19.8K | ﹤0.01% |
1,016
+997
| +5,247% | +$18.1K |
|
1768
iRadimed
IRMD
$1.05B
| $19.7K | ﹤0.01% |
412
| – | – |
|
1769
Dave & Buster's
PLAY
$239M
| $19.6K | ﹤0.01% |
440
-337
| -43% | -$12.3K |
|
1770
Movado Group
MOV
$733M
| $19.2K | ﹤0.01% |
715
-555
| -44% | -$14.5K |
|
|
CHCT
1771
Community Healthcare Trust
CHCT
$420M
| $18.6K | ﹤0.01% |
562
-6
| -1% | -$209 |
|
1772
Par Pacific Holdings
PARR
$4.19B
| $18.4K | ﹤0.01% |
693
+36
| +5% | +$851 |
|
1773
Vicor
VICR
$8.48B
| $18.4K | ﹤0.01% |
341
-3,590
| -91% | -$177K |
|
1774
Capital Bancorp
CBNK
$595M
| $18.4K | ﹤0.01% |
1,016
-225
| -18% | -$3.85K |
|
1775
DigitalOcean
DOCN
$13.9B
| $18.1K | ﹤0.01% |
451
-395
| -47% | -$14.6K |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.